Ukrainian Journal of Perinatology and Pediatrics. 2023. 2(94): 142-152; doi 10.15574/PP.2023.94.142

Naumchik A. M.¹, Davydova Iu. V.¹, Lymanska А. Yu.¹, Oliynyk V. S.^2
1SI «Institute of Pediatrics, Obstetrics and Gynecology named after academician O.M. Lukyanova of the NAMS of Ukraine», Kyiv
²MNCE «City Clinical Multidisciplinary Hospital No. 25» of the Kharkiv City Council, Ukraine

For citation: Naumchik AM, Davydova IuV, Lymanska АYu, Oliynyk VS. (2023). Clinical case of severe immune thrombocytopenia during pregnancy. Ukrainian Journal of Perinatology and Pediatrics. 2(94): 142-152; doi 10.15574/PP.2023.94.142.
Article received: Mar 01, 2023. Accepted for publication: May 30, 2023.

Immune thrombocytopenia (ITP) is one of the most common causes of thrombocytopenia (TP) in pregnancy and is the main cause of severe TP among pregnant women. Autoimmune pathogenesis determines the danger of hemorrhagic complications both for the pregnant and for the fetus and newborn. Differential diagnosis between gestational and immune thrombocytopenia is necessary, as this determines further tactics. The goal of ITP treatment is to achieve a safe level of platelets according to the gestational age and clinical situation. For treatment, different lines of therapy are used alternately with step-by-step control of effectiveness.
Purpose – to analyze the worldwide and personal experience of pregnancy management in severe ITP refractory to treatment.
We present a case of pregnancy management and delivery with a severe immune thrombocytopenia, diagnosed at 25 weeks of pregnancy with hemorrhagic syndrome, unresponsive to treatment. All pharmacological tools were used. Delivery by caesarean section with appropriate preoperative and intraoperative transfusion preparation. Recombinant human thrombopoietin was used in the postoperative period. The newborn has thrombocytopenia without hemorrhagic syndrome.
Conclusions. Correct diagnosis of conditions accompanied by thrombocytopenia during pregnancy determines the correct and effective treatment tactics.
Pregnancy and childbirth in women with severe thrombocytopenia belong to the group of extremely high risk. Antenatal management and delivery of such pregnant women should be carried out by a multidisciplinary team with the participation of a hematologist, a specialist in internal medicine, under careful control of laboratory indicators and clinical changes, with control of the fetal antenatal condition. It is necessary to control the platelet level of the newborn in the postnatal period.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: immune thrombocytopenia, pregnancy, severe thrombocytopenia, eltrombopag, recombinant human thrombopoietin.

REFERENCES

1. Alberico S, Bogatti P, Marchesan E, Cervi G, Toffoletti F. (1992). Report of a case of autoimmune thrombocytopenic purpura in pregnancy. Minerva Ginecol. 44 (7-8): 387-393.

2. American Society of Hematology. (2013). Clinical Practice Guidelines on Thrombocytopenia in Pregnancy. Thrombocytopenia – pocket-Guide. URL: https://www.academia.edu/17649565/2013_Thrombocytopenia_Pocket_Guide.

3. Amorim JG, Abecasis MR, Rodrigues FM. (2018). Refractory Severe Thrombocytopenia during Pregnancy: How to Manage. Rev Bras Ginecol Obstet. 40; 12: 803-807. https://doi.org/10.1055/s-0038-1675186; PMid:30536273

4. Bernal-Macías S, Fino-Velásquez L, Vargas-Barato F, Guerra-Galue L, Reyes-Beltrán B, Rojas-Villarraga A. (2015). Refractory Immunological Thrombocytopenia Purpura and Splenectomy in Pregnancy. Case Reports Immunol: 216362. https://doi.org/10.1155/2015/216362; PMid:26798527 PMCid:PMC4698536

5. Care A, Pavord S, Knight M, Alfirevic Z. (2018). Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. BJOG. 125 (5): 604-612. https://doi.org/10.1111/1471-0528.14697; PMid:28432736

6. Donohoe F, Higgins M, Higgins S, McAuliffe F, Murphy K. (2019). Rituximab – A novel therapy for severe ITP in pregnancy: A case report. Obstet Med. 12 (4): 196-198. https://doi.org/10.1177/1753495X18778489; PMid:31853261 PMCid:PMC6909297

7. Fadiloglu E, Unal C, Tanacan A, Portakal O, Beksac MS. (2020). 5 Yearsʼ Experience of a Tertiary Center with Thrombocytopenic Pregnancies: Gestational Thrombocytopenia, Idiopathic Thrombocytopenic Purpura and Hypertensive Disorders of Pregnancy Geburtsh Frauenheilk. 80: 76-83. https://doi.org/10.1055/a-0865-4442; PMid:31949322 PMCid:PMC6957351

8. Ferreira IJ, Sousa F, Vasco EM, Areia ALFA, Moura JPAS. (2018). Severe immune thrombocytopenia in pregnancy treated with Eltrombopag – A case report. Journal of Gynecology Obstetrics and Human Reproduction. 47 (8): 405-408. https://doi.org/10.1016/j.jogoh.2018.06.010; PMid:29981476

9. Fujimura K, Harada Y, Fujimoto T, Kuramoto A, Ikeda Y, Akatsuka J, Dan K et al. (2002). Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 75 (4): 426-433. https://doi.org/10.1007/BF02982137; PMid:12041677

10. Gernsheimer T, James AH, Stasi R. (2013). How I treat thrombocytopenia in pregnancy. Blood. 121; 1: 38-47. https://doi.org/10.1182/blood-2012-08-448944; PMid:23149846

11. Jamal S, Goel N, Mehta A, Ahuja M. (2017). Recurrent severe gestational thrombocytopenia in pregnancy: a case report. Int J Adv Med. 4: 1702-1705. https://doi.org/10.18203/2349-3933.ijam20175196

12. Kong Z, Qin P, Xiao S, Zhou H, Li H, Yang R et al. (2017). A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 31; 130 (9): 1097-1103. https://doi.org/10.1182/blood-2017-01-761262; PMid:28630121

13. Orisaka M, Shukunami K, Orisaka S, Goto K, Yoshida Y, Kotsuji F. (2005). Combination therapy for pregnant with severe refractory ITP. European Journal of Obstetrics & Gynecology and Reproductive Biology. 121: 119-120. https://doi.org/10.1016/j.ejogrb.2004.12.013; PMid:15989989

14. Pavord S, Hunt B. (2010). The Obstetric Hematology Manual. Cambridge University Press. https://doi.org/10.1017/CBO9780511676451

15. Provan D, Arnold DM, Bussel JB, Chong BH et al. (2019). Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 3; 22: 3780-3817. https://doi.org/10.1182/bloodadvances.2019000812; PMid:31770441 PMCid:PMC6880896

16. Purushothaman J, Puthumana KJ, Kumar A, Innah SJ, Gilvaz S. (2016). A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. Asian J Transfus Sci. 10 (2): 155-158. https://doi.org/10.4103/0973-6247.177204; PMid:27605856 PMCid:PMC4993088

17. Ramadan MK, Hubeich M, Itani SE, Mogharbil A. (2016). Severe Gestational Thrombocytopenia: A Case Report and Brief Review of the Literature. Journal of Hematology. 5; 4: 142-150. https://doi.org/10.14740/jh308w

18. Wang D, Liang M, Wang S. (2010). Clinical analysis of pregnancy complicated with severe thrombocytopenia. Zhonghua Fu Chan Ke Za Zhi. 45 (6): 401-405.

19. Yavaşoğlu I, Turgutkaya A. (2020). Pregnancy and immune thrombocytopenia: New trends. J Turk Ger Gynecol Assoc. 21 (2): 136-137. https://doi.org/10.4274/jtgga.galenos.2019.2019.0142; PMid:31927816 PMCid:PMC7294828